Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Phase I/II Clinical Trial to Evaluate the Safety, Tolerability and Immunogenicity of Recombinant SARS-CoV-2 Vaccine (CHO Cell) in Healthy People Aged 3 Years and Older

NCT04869592 is registered in ClinicalTrials.gov with National Vaccine and Serum Institute, China as lead sponsor.

NCT NCT04869592
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT04869592 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Phase I/II Clinical Trial to Evaluate the Safety, Tolerability and Immunogenicity of Recombinant SARS-CoV-2 Vaccine (CHO Cell) in Healthy People Aged 3 Years and Older
Lead sponsor
National Vaccine and Serum Institute, China
Phase
Phase 1/2
Overall status
Completed
Start date
April 25, 2021
Completion date
August 29, 2023
Enrollment
3,100 (actual)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

covid-19